Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BRTX | US
0.01
0.77%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.68
1.63
1.72
1.58
BioRestorative Therapies Inc. a life sciences company focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate BRTX-100 a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem) a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies Inc. has a research and development agreement with Rohto Pharmaceutical Co. Ltd.; a research agreement with Pfizer Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance Inc. and changed its name to BioRestorative Therapies Inc. in August 2011. The company was incorporated in 1997 and is based in Melville New York.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
28.6%1 month
51.6%3 months
77.3%6 months
102.5%-
-
1.07
0.01
0.01
0.13
32.72
-
-12.73M
11.61M
11.61M
-
-2.77K
-
38.10
-32.65
1.72
0.89
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.21
Range1M
0.38
Range3M
0.62
Rel. volume
1.08
Price X volume
24.57K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Edesa Biotech Inc | EDSA | Biotechnology | 3.8235 | 12.42M | -5.83% | n/a | 1.35% |
Immuron Limited | IMRN | Biotechnology | 1.96 | 11.90M | 2.62% | n/a | 1.37% |
NLS Pharmaceutics AG | NLSP | Biotechnology | 4.7601 | 11.77M | -10.19% | n/a | -18.49% |
VINC | VINC | Biotechnology | 0.3781 | 11.68M | -0.50% | n/a | 12.51% |
Brainstorm Cell Therapeutics Inc | BCLI | Biotechnology | 2.19 | 11.64M | -2.67% | n/a | -27.28% |
DOMH | DOMH | Biotechnology | 1.82 | 11.42M | 0.55% | n/a | 7.66% |
RedHill Biopharma Ltd | RDHL | Biotechnology | 8.62 | 11.04M | -1.88% | n/a | 65.80% |
Common Stock | ADXN | Biotechnology | 10.3 | 11.01M | -1.34% | n/a | 0.25% |
Mustang Bio Inc | MBIO | Biotechnology | 0.2935 | 10.93M | 35.00% | n/a | -13.03% |
Jaguar Health Inc | JAGX | Biotechnology | 1.18 | 10.90M | -3.28% | 0.25 | 176.14% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.13 | 0.53 | Cheaper |
Ent. to Revenue | 32.72 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 1.07 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 77.25 | 72.80 | Par |
Debt to Equity | 0.01 | -1.23 | Expensive |
Debt to Assets | 0.01 | 0.25 | Cheaper |
Market Cap | 11.61M | 3.66B | Emerging |